Noerr advises Zyto group on takeover by ArchiMed


Under the leadership of Thorsten Reinhard and Laurenz Tholen, Noerr has advised the shareholders of the Zyto group, which specialises in cancer diagnostics, on the takeover by the MED II Fund of French private equity firm ArchiMed.

With this takeover, ArchiMed, an investor specialising in the healthcare industry, is acquiring a fully integrated developer, manufacturer and distributor of technologically advanced tests and devices for cancer diagnostics. As part of the transaction, ArchiMed is acquiring the three operational entities Zytomed, ZytoVision and 42 Life Sciences. With ArchiMed’s support, the group is anticipated to quickly become a European market leader in diagnostics for personalised cancer therapies. The founders and managing directors of the three companies will hold a significant minority shareholding in the group.

Noerr advised the sellers extensively on structuring and implementing the transaction including their future participation in the group.

Advisors to Zyto group: Noerr Partnerschaftsgesellschaft mbB

Lead: Dr Thorsten Reinhard (Corporate/M&A, Frankfurt), Dr Laurenz Tholen (Private Equity, Berlin)


Dr Carsten Heinz (Munich)

Foreign trade

Dr Bärbel Sachs, Dr Johannes Schäffer (both Berlin)

Data privacy

Pascal Schumacher, Henrike von dem Berge (both Berlin)


Dr Stefan Schwab (Berlin), Nathalie Kibler (Hamburg)

Private equity

Dr Anna Olbrys-Sobieszuk, Alison Heinze (both Berlin) 

PR team

Mergers & Acquisitions